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A B S T R A C T
Sarcomatoid carcinoma (SC) of the lung is a rare and aggressive biphasic lung tumor with a 5-year survival of
20%. Early detection and treatment is the only way to improve outcomes in patients with SC of the lung. We
present a case of primary SC identiﬁed early based on high suspicion. A 56-year-old female with a history of
chronic obstructive pulmonary disease (COPD) presented with hemoptysis and exertional dyspnea. Chest X-ray
revealed right upper lobe (RUL) opacity and patient was started on antibiotics for pneumonia. Due to the per-
sistence of hemoptysis, a computed tomography scan was performed which showed RUL bronchiectasis with
scattered nodular opacities suggestive of an infectious process. The patient underwent bronchoscopy which
revealed a pedunculated mass in the RUL biopsy of which was consistent with poorly diﬀerentiated SC. Positron-
emission tomography scan revealed Flourdeoxyglucose-avid right peri-hilar mass and another nodule in the RUL.
The patient was not a surgical candidate because of severe COPD and was started on chemoradiation therapy. SC
of the lung can have various presentations and is usually detected at a later stage and hence, diﬃcult to treat.
Our case highlights the importance of critical thinking and prompt diagnostic evaluation in high-risk patients
with localized bronchiectasis even without an obvious lung mass on imaging.
1. Introduction
Sarcomatoid carcinoma (SC) of the lung is a very uncommon bi-
phasic lung tumor comprising of around 1% of all lung malignancies. It
is known to be an aggressive tumor with a 5-year survival of only 20%
and usually detected at later stages which make treatment options very
limited especially when there are limited guidelines available for this
rare malignancy. We present a case of SC of the lung conﬁrmed by light
microscopy and immunohistochemistry and diagnosed early in the
course of disease based on a high index of suspicion. Smoking cessation,
regular screening, early detection and treatment play a very crucial role
in improving its morbidity and mortality. SC can have various pre-
sentations and pulmonologists need to be aware of this rare form of
lung cancer and its presentations
1.1. Case
A 56-year-old female with a history of heavy smoking presented to
the emergency room with complaints of cough, fatigue, and hemoptysis
for few days prior to presentation. She reported productive cough with
blood mixed in sputum, along with shortness of breath and pleuritic
chest pain. Her other notable medical history included severe chronic
obstructive pulmonary disease (COPD), depression and family history
of lung cancer in her mother. Upon physical examination, she appeared
cachectic and had bilateral wheezing. Chest X-ray (CXR) revealed a
right upper lobe consolidation. The patient was admitted to the hospital
and started on antibiotics in the setting of COPD exacerbation and
community-acquired pneumonia. After a few days of treatment, she had
improvement in her dyspnea and chest pain. However, due to the
persistence of hemoptysis, she underwent a computed tomography (CT)
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COPD Chronic Obstructive Pulmonary Disease
CT Computed Tomography
CXR Chest X-Ray
EMA Epithelial Membrane Antigen
FDG Fluorodeoxyglucose
GCDFP Gross Cystic Disease Fluid Protein
H & E Hematoxylin and Eosin
IHI Immunohistochemical
MRI Magnetic Resonance Imaging
NSCLC Non-Small Cell Lung Carcinoma
PET Positron Emission Tomography
PDL Programmed Death Ligand
SC Sarcomatoid Carcinoma
RUL Right Upper Lobe
SMA Smooth Muscle Actin
WHO World Health Organization
WT Wilms Tumor
Fig. 1. a- Tumor cells are large in size, have vesicular nuclei and permanent nucleoli with plumpy cytoplasm. Brisk mitotic ﬁgures were also seen. b- Malignant cells
are cytokeratin CAM 5.2 focally positive. c- IHC staining showing immunoreactivity for Vimentin. d- IHC staining showing immunoreactivity for WT-1. e- IHC
staining focally positive for P63 and CK5/6. f- Tumor cells showing high Ki-67 index.
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scan of the chest which showed right upper lobe (RUL) bronchiectasis
with scattered nodular opacities suggestive of an infectious process.
There was a high suspicion of underlying malignancy in context of her
medical history and imaging ﬁndings. Therefore, a bronchoscopy was
subsequently performed that showed a right upper lobe endobronchial
lesion. The rest of the airways were patent. Bronchial washing and
endobronchial biopsy specimen analysis revealed a poorly diﬀer-
entiated malignant tumor with sarcomatoid carcinoma features.
Bronchoalveolar lavage was negative for an underlying bacterial, fungal
or tubercular infection. Immunohistochemical (IHC) staining showed
immunoreactivity for vimentin and Wilms Tumor-1 (WT-1), and focally
positive for pan-Cytokeratin (CK) AE1/AE3, P63, CK5/6, CK 8/18, CAM
5.2, Epithelial Membrane Antigen (EMA) and Gross Cystic Disease Fluid
Protein-15 (GCDFP-15). Focal weak positivity was noted in CD34 and
Smooth Muscle Actin (SMA), consistent with nonspeciﬁc staining pat-
tern. MIB1/Ki-67 labeling index was high (up to 30–50%). ( Fig. 1)
Positron-emission tomography (PET) scan revealed a 1.1 cm right
peri-hilar mass which was Fluorodeoxyglucose (FDG)-avid (SUV 8.9)
and another nodule in the RUL. Magnetic Resonance Imaging (MRI) of
her brain was negative for any metastasis. Peripheral blood cytometry
did not show any evidence of a lymphoproliferative disorder.
A diagnosis of SC of the lung, stage IIb (T3N0M0) was made. The
patient was not a candidate for surgical resection secondary to her
advanced COPD and poor pulmonary function (FEV1 of 29%). Hence,
she was started on chemoradiation therapy with weekly carboplatin
and paclitaxel and received a total of 6000 cGy of radiotherapy over 30
fractions followed by three additional cycles of consolidation che-
motherapy. A PET scan performed 6 months after the initial PET scan
showed a signiﬁcant decrease in FDG uptake in the right peri-hilar mass
and RUL nodule, suggestive of a response to the treatment. However, a
new FDG avid 0.7 cm left upper lobe nodule and 0.5 cm left lower lobe
nodule was noted concerning for the spread of malignancy. A biopsy of
the new left-sided nodules was not done as she was deemed high risk for
the procedure. Her programmed death ligand-1 (PDL-1) expression
status was not known; therefore she was started on Nivolumab. Follow-
up CT scan showed shrinkage of the nodules and our patient is currently
continuing immunotherapy. She still continues to smoke despite
smoking cessation counseling.
2. Discussion
Sarcomatoid carcinoma (SC) of the lung is an uncommon biphasic
lung tumor and comprises around 1% of all primary lung malignancies
[1–3]. It is characterized as a poorly diﬀerentiated non-small cell lung
carcinoma (NSCLC) with a component of either sarcoma-like diﬀer-
entiation (spindle and/or giant cell) or a component of true sarcoma
(malignant bone, cartilage, or skeletal muscle). The malignant carci-
nomatous component in SC is usually composed of squamous carci-
noma, adenocarcinoma, undiﬀerentiated carcinoma, or a mixture of
these elements. The sarcomatous component is usually poorly diﬀer-
entiated spindle cell sarcoma [4]. In 2004, World Health Organization
(WHO) classiﬁed SC into ﬁve subtypes based on speciﬁc histological
criteria: spindle cell carcinoma, giant cell carcinoma, pleomorphic
carcinoma, pulmonary blastoma, and carcinosarcoma. Carcinosarcoma
refers to a group of tumors that contains a mixture of carcinoma and
true sarcoma with diﬀerentiated sarcomatous elements [3].
The likely pathogenesis of SC includes malignant transformation of
cancer derived stroma, malignant transformation of hamartoma, si-
multaneous malignant transformation of epithelial elements and
stroma, sarcomatous change in carcinoma, and carcinomatous change
in sarcoma [5–7]. Some studies indicate a stem cell origin of SC from a
single totipotent stem cell that has the capacity to pursue both me-
senchymal and epithelial diﬀerentiation [8–11].
SC of the lung primarily occurs in male smokers with a higher male
to female ratio. Smoking is the main risk factor for SC, although there
have been few cases linked to asbestos exposure. The mean age for
diagnosis is 65–75 years. The average size at the time of its diagnosis is
7 cm in diameter and often invades the chest wall [3,8,12,13]. It can be
divided into two types depending on location: peripheral parenchymal
and central endobronchial. It most commonly arises as a large solitary,
peripheral mass in the upper lobes like the other smoking-related
NSCLC, but can also arise centrally [1,2,8]. There is no speciﬁc clinical
presentation for this cancer. The usual symptoms are cough, he-
moptysis, chest pain, shortness of breath, fever and weight loss. He-
moptysis is seen in around half of the cases of proximal or central tu-
mors, peripheral tumors may be asymptomatic or may present with
chest pain [14–16]. Paraneoplastic syndromes due to SC have not been
reported so far, although they are seen in around 5–8% of NSCLC [11].
Metastasis to skin, stomach, pancreas, esophagus, jejunum, rectum,
kidneys, bones, and adrenal glands and brain have been reported with
SC of the lung [7]. Park et al. reported an unusual case where a patient
initially presented with gingival exophytic mass which was rapidly
growing. Biopsy revealed metastatic carcinoma and the patient was
eventually found to have SC of the lung as the primary tumor [17].
Hence, it is also important to pay attention to the appearance of me-
tastatic symptoms of SC which could be prominent and can mislead the
diagnosis.
On gross examination, the tumor highly varies in its morphology
and is soft and ﬂeshy to ﬁrm, hard or rubbery in consistency. The cut
surface varies from white gray to tan-yellow in color with frequent
areas of hemorrhage and necrosis and occasionally shows cavitation
[2]. Imaging modalities like CT scan, MRI, and PET scan seem to be less
eﬃcient in diagnosing SC of the lung as it resembles and mimics ma-
lignant pleural mesothelioma and pulmonary aspergillosis on imaging
[18]. The IHC phenotype and histological characteristics of SC are very
diﬀerent from NSCLC, which result in its aggressive nature. Hematox-
ylin and eosin (H & E) staining may not be adequate in all cases for its
diagnosis. It is diﬃcult to distinguish SC from true sarcomas, such as
ﬁbrosarcoma and malignant ﬁbrous histiocytoma if no carcinomatous
areas are recognized on the H & E stained sections [11]. IHC stains
positive for carcinoembryonic antigen (CEA), pancreatin, EMA, CK, CD
56, chromogranin A, and synaptophysin are very speciﬁc for carcino-
matous elements, while vimentin, desmin, and smooth muscle/sarco-
meric actin conﬁrm the presence of sarcomatous components. The
tumor cells often co-express vimentin, CK, smooth muscle markers and
CEA. Therefore, the ﬁnal diagnosis is attained through IHC which has
become the gold standard for diagnosis of this tumor [13].
The treatment of SC of the lung is as challenging as the diagnosis.
There are no clearly deﬁned guidelines for the treatment of SC of the
lung as it is a rare malignancy. SC of the lung is considered to have
grave prognosis because it is an aggressive tumor with advanced local
stage and metastasis at the time of diagnosis; and refractory to che-
moradiation therapy [19]. Radical surgical resection remains the
mainstay of treatment, especially for localized tumors. Radiotherapy
and chemotherapy are being used as adjuvant therapy or in cases where
the patient is a poor surgical candidate because there seems to be a little
beneﬁt [7]. Chemotherapy used for the treatment of SC is the same as
used for NSCLCs. For metastatic cancer, no data is currently available
and SC is usually treated as NSCLC [16]. It has been seen that survival
rate at 6 months is only around 27% and the median survival is around
9 months to 1 year after a potentially curative surgical resection of the
tumor [19]. SC of the lung has a worse outcome than conventional
NSCLC. The 5-year survival rate is approximately 20% for sarcomatoid
carcinoma as compared with non-small cell lung cancer which has a 5-
year survival of 50% [7]. The early identiﬁcation of the tumor followed
by surgical and adjuvant therapy might lead to prolonged survival in
patients with SC of the lung.
3. Conclusion
Our case highlights the importance of having a high index of sus-
picions for usual and unusual lung cancers in patients presenting with
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non-speciﬁc symptoms. Pursuing further investigation can lead to a
prompt diagnosis at an early stage such as in our case allowing for
deﬁnitive treatment.
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